# Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

Study · id `cardio:ct-nct07115953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07115953](<https://clinicaltrials.gov/study/NCT07115953>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07115953

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

## Technical summary

Registry record NCT07115953. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-22 (actual); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT07115953, source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)
- Started: 2025-09-22 (actual) (ClinicalTrials.gov record NCT07115953, source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT07115953, source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)
- Completion: 2030-04-30 (anticipated) (ClinicalTrials.gov record NCT07115953, source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)
- Countries: Australia; Belgium; Germany; Greece; Ireland; Malaysia; Netherlands; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07115953, source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07115953-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
- Acronym: SWYFT
- Condition: Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Condition: Chronic Kidney Diseases
- Condition: Diabetes Mellitus
- Intervention (Device): Symplicity Spyral™ multi-electrode renal denervation system
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: 6f015a1e5e03b051b06050d4933c71732ab7ecf40587e7df9e67b93886157529
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
